New hope for aggressive breast cancer: SKB264 trial launches
NCT ID NCT06279364
First seen Jan 30, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This Phase 3 trial is testing whether a new drug called SKB264 works better than standard chemotherapy as a first treatment for people with metastatic triple-negative breast cancer (TNBC) that has spread or come back. The study will enroll about 524 participants whose tumors do not express PD-L1 or who have already received immunotherapy for early-stage disease. The main goals are to see if SKB264 helps people live longer and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB264 (a drug given by IV infusion)
What this could lead to
If it works, this could provide a new first-line treatment option for people with metastatic triple-negative breast cancer, potentially improving survival and delaying disease progression.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not prove more effective than existing chemotherapies, and side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.